Stock OCGN OCUGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Ocugen, Inc.

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
1.28 USD +8.47% Intraday chart for Ocugen, Inc. -3.03% +122.61%
22/04 Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating MT
22/04 Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating MT

Business Summary

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

Number of employees: 65

Managers

Managers TitleAgeSince
Shankar Musunuri CEO
 Chief Executive Officer 60 01/13/01
Michael Breininger DFI
 Director of Finance/CFO 42 -
Jesse Simmers CTO
 Chief Tech/Sci/R&D Officer - -
Huma Qamar CTO
 Chief Tech/Sci/R&D Officer - -
Nirdosh Jagota CMP
 Compliance Officer - -
Arun Upadhyay CTO
 Chief Tech/Sci/R&D Officer - 01/17/01
Ramesh Kumar BRD
 Director/Board Member 68 27/19/27
J.P. Gabriel PRN
 Corporate Officer/Principal - -
Michael Shine PRN
 Corporate Officer/Principal - 10/21/10
Zara Gaudioso HRO
 Human Resources Officer - 01/21/01

Members of the board

Members of the board TitleAgeSince
Marna Whittington BRD
 Director/Board Member 76 17/22/17
Prabhavathi Fernandes BRD
 Director/Board Member 74 05/20/05
Ramesh Kumar BRD
 Director/Board Member 68 27/19/27
Shankar Musunuri CEO
 Chief Executive Officer 60 01/13/01
Uday Kompella FOU
 Founder 57 01/13/01
Junge Zhang BRD
 Director/Board Member 57 01/19/01
Kirsten Castillo BRD
 Director/Board Member 51 05/20/05

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 257,446,764 253,598,862 ( 98.51 %) 121,500 ( 0.0472 %) 98.51 %
Stock B 0 54,745 0 0

Shareholders

NameEquities%Valuation
Vanguard Global Advisers LLC
4.694 %
12,039,918 4.694 % 20 M $
BlackRock Institutional Trust Co. NA
1.434 %
3,677,557 1.434 % 6 M $
Shankar Musunuri
1.230 %
3,155,168 1.230 % 5 M $
Geode Capital Management LLC
1.142 %
2,929,948 1.142 % 5 M $
Luminus Management LLC
0.6341 %
1,626,583 0.6341 % 3 M $
Junge Zhang
0.4543 %
1,165,182 0.4543 % 2 M $
STATE STREET CORPORATION
0.3259 %
835,826 0.3259 % 1 M $
Uday Kompella
0.2749 %
705,090 0.2749 % 1 M $
Northern Trust Investments, Inc.(Investment Management)
0.1987 %
509,749 0.1987 % 835 988 $
Group One Trading LP
0.1957 %
502,051 0.1957 % 823 364 $

Company contact information

Ocugen, Inc.

11 Great Valley Parkway

19355, Malvern

+

http://www.ocugen.com
address Ocugen, Inc.(OCGN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.28 USD
Average target price
6.667 USD
Spread / Average Target
+420.83%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
OCUGEN, INC. Stock Ocugen, Inc.
+122.61% 329M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. OCGN Stock
  4. Company Ocugen, Inc.